Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of fostamatinib in rheumatoid arthritis with inadequate response to DMARDs
2010-020744-35Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (3 arms), sponsored by AstraZeneca. Primary endpoint: ACR20 response at week 24. Started Jul 2010; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-020744-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020744-35.